Identification of insertion mutations in HIV-1 reverse transcriptase causing multiple drug resistance to nucleoside analogue reverse transcriptase inhibitors. NLM AIDSLINE Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Identification of insertion mutations in HIV-1 reverse transcriptase causing multiple drug resistance to nucleoside analogue reverse transcriptase inhibitors.

J Hum Virol. 1999 May-Jun;2(3):146-53. Unique Identifier : AIDSLINE MED/99339711
Sugiura W; Matsuda M; Matsuda Z; Abumi H; Okano A; Oishi T; Moriya K; Yamamoto Y; Fukutake K; Mimaya J; Ajisawa A; Taki M; Yamada K; Nagai Y; National institute of Infectious Diseases AIDS Research Center,; Tokyo, Japan. wsugiura@nih.go.jp

Abstract: OBJECTIVE: A novel 2-amino acid insertion between codons 69 and 70 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) which confers multiple drug resistance has recently been reported. Independently, we have identified similar insertion mutations in Japanese hemophiliacs and attempted to analyze their emergence in conjunction with therapy regimens and their contribution to drug resistance using recombinant technology. METHODS: The plasma and peripheral blood mononuclear cells (PBMCs) of 348 HIV-1-infected hemophiliacs were screened for HIV-1 RT mutations relevant to nucleoside analogue inhibitors and isolating viruses. Contribution of each insertion to drug resistance was studied by introducing the mutations into a T-cell line-tropic NL4-3 infectious clone and testing the drug susceptibilities of the recovered virus. RESULTS: Insertion of the 2-amino acid residue was found in 4 of the 348 cases and was strongly associated with prolonged chemotherapy with zidovudine (AZT) and didanosine (ddI). The virus isolated from 1 of the 4 cases possessed the same insertion. Characterization of these virus and the recombinant NL4-3 with the insertion strongly suggested that the insertion caused resistance not only to AZT and ddI but also to lamivudine (3TC) and zalcitabine (ddC). CONCLUSION: A 2-amino acid insertion between codons 69 and 70 of RT was detected in 4 of 348 (1.1%) Japanese hemophiliacs and was found to be associated with multiple drug resistance to nucleoside analogue RT inhibitors.
Keywords: JOURNAL ARTICLE Amino Acid Sequence Animal Anti-HIV Agents/*PHARMACOLOGY/THERAPEUTIC USE COS Cells Dideoxynucleosides/*PHARMACOLOGY/THERAPEUTIC USE Drug Resistance, Microbial/GENETICS Drug Resistance, Multiple/*GENETICS Genotype Hemophilia A/COMPLICATIONS Human HIV Infections/COMPLICATIONS/DRUG THERAPY/*VIROLOGY HIV-1/*ENZYMOLOGY/GENETICS HIV-1 Reverse Transcriptase/*GENETICS Microbial Sensitivity Tests Molecular Sequence Data *Mutagenesis, Insertional Reverse Transcriptase Inhibitors/*PHARMACOLOGY/THERAPEUTIC USE Sequence Homology, Amino Acid Support, Non-U.S. Gov'tKWDjournalarticleaminoacidsequenceanimalanti-hivagents/KWDpharmacology/therapeuticusecoscellsdideoxynucleosides/KWDpharmacology/therapeuticusedrugresistance,microbial/geneticsdrugresistance,multiple/KWDgeneticsgenotypehemophiliaa/complicationshumanhivinfections/complications/drugtherapy/KWDvirologyhiv-1/KWDenzymology/geneticshiv-1reversetranscriptase/KWDgeneticsmicrobialsensitivitytestsmolecularsequencedataKWDmutagenesis,insertionalreversetranscriptaseinhibitors/KWDpharmacology/therapeuticusesequencehomology,aminoacidsupport,non-uKWDsKWDgov't
991030
A99A0177

Copyright © 1999 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .